argenx SE (ARGX) on Decifer

Decifer ranks ARGX number 20 of 265 tracked names on durable business quality.

Why it ranks here

• It earns solid returns on the money it puts to work, around 14% and those returns have been improving.
• Revenue is growing about 90% a year, profits grew 52% over the past year, and growth is speeding up, not slowing down.
• It keeps a high share of every sale as profit, with profitability widening as it grows.
• and has the balance sheet to fund its growth.
• We do not have a clean read on how it is run yet.
• Its profit margin and growth are both unusually high right now compared to its own history, the kind of combination that often fades once conditions normalize.
• 90 percent revenue growth in a partly recognized specialty-franchise role offsets unclear quality, making it a strong growth candidate with 13 momentum.

The current read

The evidence on ARGX lines up on the supportive side: a live market force supports this name through its theme connection. The independent signals we track are telling the same story.

Themes

• Next-Gen Genetic & RNA/Antibody Therapeutics: Platform breakthroughs in RNA interference, redosable gene therapy and antibody engineering are converting once-undruggable and orphan targets into commercial therapies.

Read the full ARGX research brief · See all quality rankings

Intelligence data powered by Decifer. Not financial advice. For informational purposes only.